FDAnews

MDS NORDION SIGNS AGREEMENT WITH BRADMER FOR BRAIN CANCER THERAPEUTIC

MDS Nordion, the world's leading provider of medical isotopes and radiopharmaceutical services, has signed a three-year contract with Bradmer Pharmaceuticals for the development and clinical trial supply of Neuradiab, a monoclonal antibody conjugated to iodine-131 used to treat glioblastoma multiforme (GBM), the most common and deadly form of brain cancer.

According to the World Health Organization, GBM is usually fatal and up to 10,000 new cases are diagnosed each year in North America alone. Currently in clinical trials, to date, Neuradiab has been proven to be safe and effective in delivering tumor-killing radiation specifically to residual brain tumor cells following surgery, with minimal impact on the surrounding normal brain tissue.